Abay Taddesse, MD
Endocrinology, Diabetes & Metabolism · Hampton, VANPI 1275747891
Payments from drug & device makers
Across 9 payments — averaging $109.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$298
- Medtronic$235
- Amgen$156
- IBSA Pharma Inc.$122
- Abbott$110
- Acella Pharmaceuticals, LLC$67
What the payments were for
- Food & beverage$57959%
- Other$40841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 1 | $298 |
| Medtronic | 2 | $235 |
| Amgen | 3 | $156 |
| IBSA Pharma Inc. | 1 | $122 |
| Abbott | 1 | $110 |
| Acella Pharmaceuticals, LLC | 1 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$235
- EVENITY$125
- Tirosint$122
- FREESTYLE COPILOT$110
How this compares
$987 in reported general payments places this provider in the 40th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 232 | $386,874 |
| TrulicityDulaglutide | 138 | $283,351 |
| JardianceEmpagliflozin | 106 | $159,815 |
| FarxigaDapagliflozin Propanediol | 105 | $138,382 |
| RybelsusSemaglutide | 65 | $130,349 |
| MounjaroTirzepatide | 80 | $97,442 |
| JanuviaSitagliptin Phosphate | 81 | $97,109 |
| GlyxambiEmpagliflozin/Linagliptin | 67 | $96,191 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 445 | $86,140 |
| JanumetSitagliptin Phos/Metformin Hcl | 53 | $69,441 |
| Novolog FlexpenInsulin Aspart | 188 | $58,212 |
| ForteoTeriparatide | 12 | $51,479 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $48,964 |
| Repatha SureclickEvolocumab | 33 | $47,320 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $46,476 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Hampton
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
- Samamtha HudsonMidlothian$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.